Diagnostical and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) 307.51: Binge-Eating Disorder (ICD-10: F50.8) E66
Conditions
Interventions
Group 1: Acceptance-based behavioral therapy with smartphone support
Group 2: Waitlist
Sponsors
Forschungsbereich Verhaltensmedizin, Integriertes Forschungs- und Behandlungszentrum AdipositasErkrankungen, Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin Leipzig
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The OB+BED sample will consist of individuals with BED according to DSM-5 as determined through the Eating Disorder Examination interview and BMI 30.0-45.0 kg/m2. 2. The OB-BED sample will consist of individuals without BED and with BMI 30.0-45.0 kg/m2. 3. The NW sample will include individuals without BED and with BMI 18.5-25.0 kg/m2. Additional general inclusion criteria are: 4. Informed consent 5. Sufficient German language skills and a feasible commute to the medical campus of Leipzig University
Exclusion criteria
Exclusion criteria: 1. Serious somatic conditions (e.g., neurological disorders, stroke, head injury, manifest diabetes, severe hypertension) 2. Serious mental disorders (e.g., psychotic disorder, suicidality, substance use disorder, ADHD, depression, anxiety disorder), as determined by the clinical interview Mini-DIPS, and developmental or intellectual disability 3. Medication acting on the central nervous system; use of anorexic medication or other interventions for weight loss in the past 6 months 4. Ongoing psychotherapy; past or present history of alcohol misuse or the use of illegal drugs (ensured by urine screening) 5. Pregnancy or breast-feeding females, or persons being held by judicial or official order, or other contraindications for the use of radiotracers according to the radiation protection legislation; Women of child bearing potential will be interviewed regarding a potential pregnancy and in addition urine pregnancy testing will be performed prior to the administration of [11C]MRB using a standard kit. 6. MRI contraindications such as ferromagnetism (e.g., pacemaker, drug-delivery systems), or claustrophobia; there will be no application of contrast media 7. To avoid interference of ethanol with the radiopharmaceutical, the use of any alcoholic beverages and/or other compounds that include alcohol is prohibited for at least 48 hours prior to PET investigation. The use of medical drugs which inhibit the reboxetine-degrading liver enzyme (such as ketoconazol or fluvoxamine), which interact with reboxetine (e.g., monoamine-oxidase inhibitors or lorazepam), or which may displace [11C]MRB from the binding site (such as atomoxetine or nisoxetine) is excluded as well.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regional distribution volume as an index of noradrenaline transporter (NAT) availability in the brain at baseline (OB+BED, OB-BED, NW) and before and after intervention (OB+BED, OB-BED) | — |
Secondary
| Measure | Time frame |
|---|---|
| Resting-state and task-related fMRI and behavioral data; clinical interviews and self-report questionnaires on eating behavior, emotion regulation, mental and physical health, and quality of life; neuropsychological tests | — |
Countries
Germany
Contacts
Public ContactAnja Hilbert
Forschungsbereich Verhaltensmedizin, Integriertes Forschungs- und Behandlungszentrum AdipositasErkrankungen, Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin Leipzig
Outcome results
None listed